StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Invivyd Inc. (IVVD)

Wed, 08 Jul 2026 06:43:57 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Invivyd Inc. (NASDAQ: IVVD).

The analyst commented: "On July 6, 2026, Invivyd announced that the FDA issued a Notice of Termination for the PEMGARDA (pemivibart) Emergency Use Authorization (EUA), following the U.S. Department of Health and Human Services' (HHS) June 30 advanced Notice of Termination of the COVID-19 EUA declaration, with both effective June 29, 2027, after a 12-month transition period. In a follow-up call with Invivyd's Chairman Marc Elia, Chief Financial Officer Bill Duke, and Senior Vice President of Finance Katie Falzone, management reiterated that an

Form 8-K Invivyd, Inc. For: Jul 06

Mon, 06 Jul 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260706/26732629.html

Form 8-K Invivyd, Inc. For: Jul 06

Mon, 06 Jul 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260706/26732629.html

FDA notifies Invivyd that Pemgarda EUA will end June 2027

Mon, 06 Jul 2026 07:06:19 -0400

Invivyd, Inc. (Nasdaq: IVVD) announced that the U.S. Food and Drug Administration has issued a Notice of Termination for the Emergency Use Authorization (EUA) of its COVID-19 prevention drug Pemgarda (pemivibart), with an effective termination date of June 29, 2027.

The notice follows a June 30, 2026 announcement by the U.S. Department of Health and Human Services that it would terminate the COVID-19 EUA declaration, also effective June 29, 2027, providing a twelve-month transition period.

Pemgarda has been authorized under an EUA since March 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents with moderate-to-severe immune compromise who are unlikely to

FDA notifies Invivyd that Pemgarda EUA will end June 2027

Mon, 06 Jul 2026 07:06:19 -0400

Pemgarda has been authorized under an EUA since March 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents with moderate-to-severe immune compromise who are unlikely to

FDA notifies Invivyd that Pemgarda EUA will end June 2027

Mon, 06 Jul 2026 07:06:19 -0400

Pemgarda has been authorized under an EUA since March 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents with moderate-to-severe immune compromise who are unlikely to

FDA notifies Invivyd that Pemgarda EUA will end June 2027

Mon, 06 Jul 2026 07:06:19 -0400

Pemgarda has been authorized under an EUA since March 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents with moderate-to-severe immune compromise who are unlikely to

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Mon, 06 Jul 2026 07:01:00 -0400

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027
Consequently, Invivyd received from the U.S. Food and Drug Administration (FDA) Notice of Termination of the PEMGARDA EUA, to be effective on June 29, 2027, after a twelve-month transition period
Consistent with EUA transition processes, Invivyd is in dialogue with FDA about appropriate next steps for PEMGARDA
Invivyd intends to pursue every avenue to secure permanent, high quality medical protection from COVID infection for immune-compromised and other vulnerable Americans
PEMGARDA has demonstrated strong protection from COVID in a contemporary randomized

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Mon, 06 Jul 2026 07:01:00 -0400

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027
Consequently, Invivyd received from the U.S. Food and Drug Administration (FDA) Notice of Termination of the PEMGARDA EUA, to be effective on June 29, 2027, after a twelve-month transition period
Consistent with EUA transition processes, Invivyd is in dialogue with FDA about appropriate next steps for PEMGARDA
Invivyd intends to pursue every avenue to secure permanent, high quality medical protection from COVID infection for immune-compromised and other vulnerable Americans
PEMGARDA has demonstrated strong protection from COVID in a contemporary randomized

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Mon, 06 Jul 2026 07:01:00 -0400

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027
Consequently, Invivyd received from the U.S. Food and Drug Administration (FDA) Notice of Termination of the PEMGARDA EUA, to be effective on June 29, 2027, after a twelve-month transition period
Consistent with EUA transition processes, Invivyd is in dialogue with FDA about appropriate next steps for PEMGARDA
Invivyd intends to pursue every avenue to secure permanent, high quality medical protection from COVID infection for immune-compromised and other vulnerable Americans
PEMGARDA has demonstrated strong protection from COVID in a contemporary randomized

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

Mon, 06 Jul 2026 07:01:00 -0400

U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027
Consequently, Invivyd received from the U.S. Food and Drug Administration (FDA) Notice of Termination of the PEMGARDA EUA, to be effective on June 29, 2027, after a twelve-month transition period
Consistent with EUA transition processes, Invivyd is in dialogue with FDA about appropriate next steps for PEMGARDA
Invivyd intends to pursue every avenue to secure permanent, high quality medical protection from COVID infection for immune-compromised and other vulnerable Americans
PEMGARDA has demonstrated strong protection from COVID in a contemporary randomized

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:01:00 -0400

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8544, representing the closing price of Invivyd’s common stock on the grant date. Each

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:01:00 -0400

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8544, representing the closing price of Invivyd’s common stock on the grant date. Each

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:01:00 -0400

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8544, representing the closing price of Invivyd’s common stock on the grant date. Each

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:01:00 -0400

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8544, representing the closing price of Invivyd’s common stock on the grant date. Each

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Mon, 29 Jun 2026 07:00:00 -0400

ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative medicines for areas of significant unmet need, today announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Company's Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities. Dr. Fu will support the Company in an advisory capacity during the transition.

Dr. Gupta is an experienced CEO who brings more than two